{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:28:56Z","timestamp":1761182936531,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jiac.2017.09.009","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T15:24:39Z","timestamp":1507821879000},"page":"138-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Disseminated cryptococcosis in a patient taking tocilizumab for Castleman's disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Hiroaki","family":"Nishioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.09.009_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/s10165-010-0279-5","article-title":"Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions","volume":"20","author":"Nishimoto","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jiac.2017.09.009_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jiac.2017.09.009_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.diagmicrobio.2006.10.014","article-title":"Cryptococcal meningitis in a patient treated with infliximab","volume":"57","author":"Mu\u00f1oz","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2017.09.009_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jiac.2017.09.009_bib5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/424455","article-title":"Granulomatous infections due to tumor necrosis factor blockade: correction","volume":"39","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.09.009_bib6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.09.009_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1439-0507.2007.01357.x","article-title":"Serotype identification of Cryptococcus neoformans by multiplex PCR","volume":"50","author":"Ito-Kuwa","year":"2007","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2017.09.009_bib8","unstructured":"Available from: https:\/\/chugai-pharm.jp\/hc\/ss\/pr\/bone\/drug\/act_via0080\/se\/ser\/index.html [in Japanese] [Accessed 27 May 2017]."},{"key":"10.1016\/j.jiac.2017.09.009_bib9","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jiac.2017.09.009_bib10","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jiac.2017.09.009_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-011-0488-6","article-title":"Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab","volume":"22","author":"Hoshi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jiac.2017.09.009_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/s10165-008-0111-7","article-title":"Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases","volume":"19","author":"Fujiwara","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jiac.2017.09.009_bib13","article-title":"The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment","volume":"2012","author":"Yanagawa","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jiac.2017.09.009_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0167-4889(91)90207-E","article-title":"Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and\/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes","volume":"1091","author":"Yap","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jiac.2017.09.009_bib15","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.4049\/jimmunol.155.5.2557","article-title":"Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice","volume":"155","author":"Szalai","year":"1995","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jiac.2017.09.009_bib16","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.jiac.2017.09.009_bib17","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1086\/593174","article-title":"Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis","volume":"198","author":"Harris","year":"2008","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2017.09.009_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ibd.21384","article-title":"Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis","volume":"17","author":"Terabe","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jiac.2017.09.009_bib19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/clinids\/14.3.666","article-title":"Cryptococcal disease presenting as cellulitis","volume":"14","author":"Anderson","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.09.009_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2340\/00015555-1385","article-title":"Cryptococcal cellulitis in a patient with bullous pemphigoid","volume":"93","author":"Sugiura","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jiac.2017.09.009_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3855\/jidc.2479","article-title":"Disseminated Cryptococcosis presenting as cellulitis in a renal transplant recipient","volume":"7","author":"Chaya","year":"2013","journal-title":"J\u00a0Infect Dev Ctries"},{"key":"10.1016\/j.jiac.2017.09.009_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000360978","article-title":"Disseminated cryptococcosis-induced skin ulcers in a patient with autoimmune hepatitis","volume":"6","author":"Ikeda","year":"2014","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jiac.2017.09.009_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/345956","article-title":"French Cryptococcosis Study Group. Primary cutaneous cryptococcosis: a distinct clinical entity","volume":"36","author":"Neuville","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.09.009_bib24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archinte.1994.00420090124014","article-title":"Disseminated cutaneous cryptococcosis. Comparison of clinical manifestations in the pre-AIDS and AIDS eras","volume":"154","author":"Pema","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jiac.2017.09.009_bib25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/0190-9622(95)91544-3","article-title":"Cutaneous manifestations of disseminated cryptococcosis","volume":"32","author":"Dimino-Emme","year":"1995","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17302118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17302118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:57:12Z","timestamp":1761159432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17302118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1341321X17302118"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.09.009","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disseminated cryptococcosis in a patient taking tocilizumab for Castleman's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}